After the discovery of its role in tumor evasion of immune surveillance, CD47 has become a novel biomarker for cancer immunotherapy, and several anti-CD47 antibodies have been studied, including B6H12, Hu5F9-G4, and ZF1 [34,35,36]. The gene discussed is CD47; the disease is neoplasm.